Losartan as a Steroid-Sparing Adjunct in a Patient With Features of Refractory Camurati-Engelmann Disease
Open Access
- 1 March 2022
- journal article
- case report
- Published by Elsevier BV in AACE Clinical Case Reports
- Vol. 8 (2), 54-57
- https://doi.org/10.1016/j.aace.2021.08.002
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Elimination of Pain and Improvement of Exercise Capacity in Camurati-Engelmann Disease With LosartanJournal of Clinical Endocrinology & Metabolism, 2014
- Emerging Roles for the Transforming Growth Factor-β Superfamily in Regulating Adiposity and Energy ExpenditureEndocrine Reviews, 2010
- Skull Base Manifestations of Camurati-Engelmann DiseaseJAMA Otolaryngology–Head & Neck Surgery, 2010
- Painful Lower Extremities Related to Diaphyseal Dysplasia: Genetic Diagnosis and TreatmentThe Journal of Rheumatology, 2009
- Immunoneutralization of TGF1 Improves Skeletal Muscle Regeneration: Effects on Myoblast Differentiation and Glycosaminoglycan ContentInternational Journal of Cell Biology, 2009
- Camurati-Engelmann disease: review of the clinical, radiological, and molecular data of 24 families and implications for diagnosis and treatmentJournal of Medical Genetics, 2005
- Marked phenotypic variability in progressive diaphyseal dysplasia (Camurati–Engelmann disease): Report of a four‐generation pedigree, identification of a mutation in TGFB1, and reviewAmerican Journal of Medical Genetics Part A, 2004
- Role of transforming growth factor-beta in bone remodeling.1990
- Role of Transforming Growth Factor-Beta in Bone RemodelingClinical Orthopaedics and Related Research, 1990
- In VivoStimulation of Bone Formation by Transforming Growth Factor-βEndocrinology, 1989